Page last updated: 2024-08-17

medroxyprogesterone acetate and Hematologic Diseases

medroxyprogesterone acetate has been researched along with Hematologic Diseases in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bunce, CM; Craddock, CF; Drayson, MT; Hayden, RE; Holyoake, TL; Jackson, N; Khanim, FL; Lumley, M; Murray, JA1

Trials

1 trial(s) available for medroxyprogesterone acetate and Hematologic Diseases

ArticleYear
Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML).
    British journal of haematology, 2010, Volume: 149, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bezafibrate; Female; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Medroxyprogesterone Acetate; Middle Aged; Recurrence; Treatment Outcome

2010